Little evidence for involvement of MLH3 in colorectal cancer predisposition

Open Access
Publisher Website
Google Scholar
Abstract
Mutations in the DNA MMR genes MSH2, MLH1, MSH6 and PMS2 underlie a large subset of HNPCC cases, and a hallmark of the tumors is MSI. In many HNPCC families, however, a causative mutation has not been found. Therefore, the involvement of additional, thus far unknown, genes in MSI as well as MSS colorectal tumor predisposition is possible. The role of a relatively recently cloned MMR gene, MLH3, in familial CRC has been studied; but the results appear somewhat conflicting. To further evaluate the role of MLH3 in CRC predisposition, we analyzed 30 Finnish CRC cases for germline mutations by sequencing. These cases were selected from a large series of Finnish CRC patients, to match features previously proposed to associate with MLH3 germline defects. We found 5 missense variants, 4 of which were also found in Finnish cancer‐free controls. The only remaining variant does not appear to be an attractive candidate for a disease‐associated mutation because the amino acid change is located outside the conserved residues. We also screened for the previously reported variants, including a frameshift change, the most likely pathogenic MLH3 mutation observed so far. The frameshift was not present in the 30 CRC cases or in 700 cancer‐free controls. While it is a difficult task to exclude a role of MLH3 in HNPCC, our study could not confirm a role for MLH3 in CRC predisposition.
Funding Information
  • European Commission (QLG2-CT-2001-01861)
  • Finnish Cancer Society
  • Academy of Finland
  • Sigrid Juselius Foundation
  • Duodecim
  • Ida Montin Foundation
  • Jalmari and Rauha Ahokas Foundation
  • Emil Aaltonen Foundation
  • Helsingin Sanomat Foundation
  • Ella and Georg Ehrnrooth Foundation
  • Finnish-Norwegian Medical Foundation
  • Nordisk Cancer Union
  • Paulo Foundation
  • Finnish Cultural Foundation
  • Helsinki University Central Hospital